Type 2 Diabetes

Dr Diana Isaacs provides an overview of the latest developments in oral insulin to manage patients with diabetes.

Drs Diana Isaacs and Natalie Bellini compare dosing of inhaled insulin to injectable insulin for the management of diabetes.

The last full weekend of each month, our editorial team compiles a list of our most popular endocrinology content from the past month for a month in review recap. The December 2022 endocrinology month in review features coverage of the FDA’s clearance of Dexcom G7, new data related to use of SGLT2 inhibitors in pediatric type 2 diabetes, and the ADA's Standards of Care in Diabetes—2023.

In the December 2022 episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to discuss recent developments in the field, with a spotlight on the Dexcom G7 CGM, key takeaways from the ADA’s Standards of Care in Diabetes—2023, and perspective from the ADCES Diabetes Technology Conference 2022.

Data from the nuMoM2b study suggests greater adherence to a Mediterranean diet was associated with reductions of 37%, 28%, and 21% in odds of gestational diabetes, preeclampsia, and any adverse pregnancy outcome, respectively, among a cohort of more than 7000 nulliparous women.

Kimberly Simmons, MD, reviews stages 1, 2, and 3 of pediatric T1D progression.

Tina Q Tan, MD, and Kimberly Simmons, MD, provide an overview of the prevalence of type 1 diabetes (T1D) in pediatric patients as well as its risk factors.

In this episode of Diabetes Dialogue, Jill Weissberg-Benchell, PhD, takes hosts through her journey to becoming a diabetes care and education specialist, the role of psychologists in the management of pediatric diabetes, and her thoughts on the evolving role of care and education specialists in the management of diabetes.

Anti-obesity medications have the potential for significant weight reduction, but the development of newer agents may lead to an even greater change in obesity care.

In this episode of Diabetes Dialogue, Richard Bergenstal, MD, sits down with hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss the role and evolution of technology in the management of diabetes.

An analysis of NHANES data spanning more than 3 decades provides an overview of trends in glycemic control and severe hyperglycemia among people with diabetes using insulin, including racial and ethnic disparities.

Dr Diana Isaacs and Dr Natalie Bellini review adverse effects of inhaled insulin in patients with T1D and T2D.

An expert endocrine clinical pharmacist and nurse practitioner discuss clinical trial data on how inhaled insulin affects glucose management in T1D and T2D.

An analysis of a national health insurance database provides insight into the risk of total knee or total hip replacement based on use of metformin among a cohort of older adults.

Using data from Medicare Advantage beneficiaries from 2011-2020, investigators provide an overview of trends of severe hyperglycemic- and hypoglycemic-related hospitalizations and emergency department visits among those with type 1 or type 2 diabetes.

A systematic review and meta-analysis of studies reporting the pooled prevalence of obesity in pediatric type 2 diabetes suggest 75% of these patients had obesity.

Reflections on a century's worth of developments toward a major breakthrough in T1D this year.

In this episode of Diabetes Dialogue, Jane Jeffrie Seley, DNP, MPH, a member of the writing committee for the ADA's Standards of Care in Diabetes—2023, joins the podcast to discuss pertinent updates in the sections of the document discussing inpatient management of diabetes within the document.

Drs Diana Isaacs and Natalie Bellini share the FDA-approved patient populations for inhaled insulin use to manage diabetes, as well as who would not be a good candidate.

Experts examine the use of Technosphere insulin, how it is delivered to the body, and the qualities of an ideal rapid-acting insulin analog in type 1 and type 2 diabetes.

Published on December 12, the latest Standards of Care in Diabetes from the American Diabetes Association contain more than 100 new updates related to management and diagnosis of all types of diabetes.

Eli Lilly and Company and Boehringer Ingelheim announced their SGLT2 inhibitor, empagliflozin, was associated with statistically significant reductions in HbA1c relative to placebo therapy among a population of pediatric patients with type 2 diabetes in the DINAMO trial.

Data from the BCQR-T1D study, which was funded by the National Institutes of Health, suggest use of the dopamine receptor agonist bromocriptine was associated with improved blood pressure and arterial stiffness after 4 weeks of treatment in youth with type 1 diabetes.

Drs Diana Isaacs and Natalie Bellini discuss the limitations of injectable insulins in achieving time-in-range and glucose targets in type 1 and type 2 diabetes.